
Allogene: Pioneering Allogeneic CAR-T Developer With No Near-Term Catalysts (NASDAQ:ALLO)
Ekaterina Chizhevskaya/iStock via Getty Images In my previous article, we saw how Allogene Therapeutics, Inc. (NASDAQ:ALLO) came out of that clinical hold on its ALLO501A product for its phase 1 Non-Hodgkin Lymphoma (NHL) trial. I […]